FDA committee unanimously backs Moderna vaccines for children, adolescents

An FDA advisory committee on Tuesday unanimously backed Moderna’s COVID-19 vaccines for children and adolescents aged 6 to 17 years.
Members of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 22-0 to recommend that the FDA amend Moderna’s emergency use authorization (EUA) to make the company’s vaccine available for a pediatric population for the first time, saying the benefits outweigh the risks.
The FDA will now consider the VRBPAC’s recommendations. The EUAs would be for a two-dose series for adolescents aged 12 through 17 years at 100 g

An FDA advisory committee on Tuesday unanimously backed Moderna’s COVID-19 vaccines for children and adolescents aged 6 to 17 years.
Members of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 22-0 to recommend that the FDA amend Moderna’s emergency use authorization (EUA) to make the company’s vaccine available for a pediatric population for the first time, saying the benefits outweigh the risks.
The FDA will now consider the VRBPAC’s recommendations. The EUAs would be for a two-dose series for adolescents aged 12 through 17 years at 100 g